Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Twist Bioscience Raises Funds Through Public Offering

PUBLIC · TWSTAug 04, 2026•6 days ago

Amount Raised

$300 Million

Round Type

Post-IPO Equity

San FranciscoManufacturingBiotechnology

Investors

Guggenheim Securities, LlcLeerink Partners LlcWilliam Blair & Company, L.L.C.Goldman Sachs & Co. Llc

Description

On August 4, 2026, Twist Bioscience Corporation announced an underwriting agreement to sell shares of its common stock. The company will issue 3,125,000 shares at a public offering price of $96.00 per share. Additionally, the underwriters have an option to purchase up to 468,750 more shares within 30 days of the offering. This funding will support the company’s expansion and ongoing projects.

Company Information

Company

Twist Bioscience

Location

455 MISSION BAY BOULEVARD SOUTH

San Francisco, California, United States

About

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. Follow us on Twitter | Facebook | LinkedIn | YouTube

Related People

Suggested for you
1 contact
Verified contacts26 people are listed at Twist Bioscience — we don't have their email yet.
Predictive Intelligence
Strategic

ML-powered predictions for Twist Bioscience's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.